Related Experiment Video
Updated: Sep 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Mechanistic studies to understand the inhibition of wild type and mutant HIV-1 reverse transcriptase by
1Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06520-8066, USA.
Abstract:
Abacavir (1592U89) has recently been approved by the FDA for treatment of HIV infection. Transient kinetic studies were carried out to better understand the interaction of the active metabolite of Abacavir (Carbovir-triphosphate) with wild type and mutant HIV-1 reverse transcriptase. Some of the data is summarized and used as a basis for discussion of inhibition by CBVTP and previously studied nucleoside analogs.
More Related Videos
13:07Determining 3'-Termini and Sequences of Nascent Single-Stranded Viral DNA Molecules during HIV-1 Reverse Transcription in Infected Cells
Published on: January 30, 2019
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Retrovirus Life Cycles
Size and Structure of Viral Genomes
Viruses with RNA Genomes
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly